Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03733730 · ClinicalTrials.gov registry record · NA
Post Approval Study of the AcrySof® IQ ReSTOR® Toric IOLs
A NA study, sponsored by Alcon Research.
- Completed
- Registry status
- NA
- Development phase
- 2,449
- Enrollment target
NCT03733730: Completed NA study, sponsored by Alcon Research.
NCT03733730 is a NA study that has completed, run by Alcon Research. The registered enrollment target is 2,449 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03733730, a NA study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,449 participants
- Enrollment target
Study Summary
This is a prospective, multicenter, post-approval active surveillance study. The purpose of this study is to report the rate of post-surgical intraocular inflammation (based upon a specified case definition) reported within a 180-day post-surgical period following attempted implantation of an ACRYSOF IQ RESTOR Toric or ACRYSOF IQ RESTOR IOL in the US.
Primary Outcome
Post-surgical intraocular inflammation was defined as exacerbated intraocular inflammation within 180 days after IOL implantation, indicated by greater than or equal to 3+ aqueous cell within the first 14 days post-operative, and/or greater than or equal to 2+ aqueous cell greater than 14 days and less than or equal to 60 days post-operative, and/or greater than or equal to 1+ aqueous cell greater than 60 days post-operatively or later. The event rate (per 1000 IOL implants) was calculated as "T
Interventions
- PROCEDURE Cataract Surgery
- DEVICE ACRYSOF IQ RESTOR +3.0 Multifocal Toric IOL
- DEVICE ACRYSOF IQ RESTOR +2.5 D Multifocal Toric IOL
- DEVICE ACRYSOF IQ RESTOR +2.5 D Multifocal IOL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,449 participants |
| Start Date | 2018-11-27 |
| Est. Completion | 2022-10-14 |
| Phase | NA |
What the finished NCT03733730 record still lists
NCT03733730 is an interventional study that assigns participants to a tested intervention. Its 2,449 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% higher).
The record links to 0 conditions, and to 4 interventions - of which Cataract Surgery is the first listed.
NCT03733730 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03733730 about?
NCT03733730 is a clinical study titled "Post Approval Study of the AcrySof® IQ ReSTOR® Toric IOLs". This is a prospective, multicenter, post-approval active surveillance study. The purpose of this study is to report the rate of post-surgical intraocular inflammation (based upon a specified case definition) reported within a 180-day post-surgical period following attempted implantation of an ACRYSO...
What is the current status of trial NCT03733730?
This trial is currently completed. It is a NA study. The enrollment target is 2,449 participants. The study started on 2018-11-27. Estimated completion is 2022-10-14.
What interventions are being tested in trial NCT03733730?
The interventions under investigation include: Cataract Surgery (PROCEDURE), ACRYSOF IQ RESTOR +3.0 Multifocal Toric IOL (DEVICE), ACRYSOF IQ RESTOR +2.5 D Multifocal Toric IOL (DEVICE), ACRYSOF IQ RESTOR +2.5 D Multifocal IOL (DEVICE).
Who is sponsoring clinical trial NCT03733730?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03733730's enrollment target sits among peer trials
2,449 45th of 2000 higher than 1,956 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06898593 · 2,448 participants · NA
Enhancing Engagement by Integrating Goals and Concerns That Matter to Patients
- NCT06128304 · 2,436 participants · NA
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
- NCT06676904 · 2,433 participants · NA
Neonatal Platelet Transfusion Threshold Trial
- NCT05345951 · 2,425 participants · NA
Project e-PBI+ - Parent Intervention to Reduce College Student Drinking and Cannabis Use
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI